Yarrow Bioscience Inc

YARW · NasdaqCM · Stock · Healthcare

$18.90

+1.61% today

Delayed price, 2026-10-15 11:07 UTC

What Yarrow Bioscience does

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Key facts

Sector

Healthcare

Industry

Biotechnology

Market cap

$175.9M

P/E (ttm)

—

Forward P/E

-11.5

Dividend yield

0.00%

Beta

2.08

Profit margin

0.0%

Employees

Headquarters

New York, NY, United States

Exchange

NasdaqCM

Website

www.yarrowbioscience.com

Performance

1 Month

-35.5%

3 Months

-50.3%

6 Months

-38.0%

1 Year

+0.0%

5 Years

-98.0%

$16.0552-week range$46.95

Biggest setback — last 12 months

-55.5%

10 Aug 2026 → 12 Oct 2026

Fell from $42.49 to $18.90 — its sharpest sustained decline this year.

Biggest run-up — last 12 months

+141.4%

3 Nov 2025 → 10 Aug 2026

Ran from $17.60 to $42.49 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▼ Trend: Downtrend

Price is below its 20-, 50- and 200-day averages, each stacked below the next — a classic technical downtrend structure.

Horizon	Bear case (−1σ)	Base case	Bull case (+1σ)
1 Month	$13.61 (-28.0%)	$18.90	$26.24 (+38.9%)
3 Months	$10.70 (-43.4%)	$18.90	$33.37 (+76.6%)
6 Months	$8.46 (-55.2%)	$18.90	$42.23 (+123.5%)
12 Months	$6.06 (-67.9%)	$18.90	$58.92 (+211.8%)

Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 113.7%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Amphastar Pharmaceuticals, Inc.

$26.08 · +0.1%

LBRX

LB Pharmaceuticals Inc

Learn the basics

What is a stock? Understanding risk and reward Why diversification matters

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.